Biomerica, Inc. (BMRA) Analysts See $-0.08 EPS

Biomerica, Inc. (NASDAQ:BMRA) Logo
Investors sentiment decreased to 1 in 2019 Q2. Its down 0.50, from 1.5 in 2019Q1. It dropped, as 2 investors sold Biomerica, Inc. shares while 2 reduced holdings. 3 funds opened positions while 1 raised stakes. 120,162 shares or 4.01% less from 125,183 shares in 2019Q1 were reported.
Bard Assoc Inc has invested 0.01% of its portfolio in Biomerica, Inc. (NASDAQ:BMRA). Blackrock Incorporated holds 0% of its portfolio in Biomerica, Inc. (NASDAQ:BMRA) for 5,112 shares. California-based Wells Fargo Mn has invested 0% in Biomerica, Inc. (NASDAQ:BMRA). 16 were reported by Royal Comml Bank Of Canada. 15,550 were accumulated by Heritage Investors Mgmt. Tower Rech Capital Llc (Trc) holds 0% or 1,094 shares in its portfolio. Panagora Asset Mgmt Inc holds 0% or 2,200 shares. Susquehanna Group Inc Inc Llp stated it has 0% in Biomerica, Inc. (NASDAQ:BMRA). Vanguard Group Incorporated stated it has 0% of its portfolio in Biomerica, Inc. (NASDAQ:BMRA). Moreover, State Bank Of America Corporation De has 0% invested in Biomerica, Inc. (NASDAQ:BMRA). Perritt Cap Mgmt holds 40,000 shares.

Analysts expect Biomerica, Inc. (NASDAQ:BMRA) to report $-0.08 EPS on October, 15.They anticipate $0.03 EPS change or 60.00 % from last quarter’s $-0.05 EPS. After having $-0.08 EPS previously, Biomerica, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 4.17% or $0.125 during the last trading session, reaching $2.875. About 34,178 shares traded or 0.68% up from the average. Biomerica, Inc. (NASDAQ:BMRA) has declined 7.84% since September 12, 2018 and is downtrending. It has underperformed by 7.84% the S&P500.

Biomerica, Inc., together with its subsidiaries, develops, makes, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company has market cap of $27.01 million. The companyÂ’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It currently has negative earnings. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests.

More notable recent Biomerica, Inc. (NASDAQ:BMRA) news were published by: Globenewswire.com which released: “Biomerica Announces Second Quarter Financial Results Nasdaq:BMRA – GlobeNewswire” on January 15, 2019, also Globenewswire.com with their article: “Liolios 7th Annual Gateway Conference to Showcase 100 Leading Companies at the Four Seasons San Francisco September 5-6, 2018 – GlobeNewswire” published on August 06, 2018, Globenewswire.com published: “Biomerica Announces First Patient Enrollment in Clinical Study for New Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy – GlobeNewswire” on June 25, 2018. More interesting news about Biomerica, Inc. (NASDAQ:BMRA) were released by: Finance.Yahoo.com and their article: “Cannabis players vie for piece of $17 billion industry at weed conference – Yahoo Finance” published on February 13, 2019 as well as Globenewswire.com‘s news article titled: “Biomerica Extends Exclusive License Agreement with Celtis Pharm (Telcon Pharmaceuticals) to December 2019 – GlobeNewswire” with publication date: November 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.